These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 21605990

  • 1. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
    Tsuji S, Kasumi T, Nagase K, Yoshikawa E, Kobayashi H, Kurita N.
    J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
    [Abstract] [Full Text] [Related]

  • 2. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K, Kobayashi H, Yoshikawa E, Kurita N.
    J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
    [Abstract] [Full Text] [Related]

  • 3. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
    De Souza M, Matthews H, Lee JA, Ranson M, Kelso MJ.
    Bioorg Med Chem; 2011 Apr 15; 19(8):2549-56. PubMed ID: 21454081
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Structural investigations of recombinant urokinase growth factor-like domain.
    Beloglazova IB, Beabealashvilli RSh, Gursky YG, Bocharov EV, Mineev KS, Parfenova EV, Tkachuk VA.
    Biochemistry (Mosc); 2013 May 15; 78(5):517-30. PubMed ID: 23848154
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH, Grimbergen JM, Lansink M, Bakker AH, Blatter MC, Belin D, van Hinsbergh VW, Verheijen JH.
    Arterioscler Thromb Vasc Biol; 1998 May 15; 18(5):693-701. PubMed ID: 9598826
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.